EP1557197A1 - Dihydroalkoxybenzyloxopyrimidin (dabo) Derivative mit spermizider Wirkung - Google Patents

Dihydroalkoxybenzyloxopyrimidin (dabo) Derivative mit spermizider Wirkung Download PDF

Info

Publication number
EP1557197A1
EP1557197A1 EP04030236A EP04030236A EP1557197A1 EP 1557197 A1 EP1557197 A1 EP 1557197A1 EP 04030236 A EP04030236 A EP 04030236A EP 04030236 A EP04030236 A EP 04030236A EP 1557197 A1 EP1557197 A1 EP 1557197A1
Authority
EP
European Patent Office
Prior art keywords
sperm
pbt
compound
dabo
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04030236A
Other languages
English (en)
French (fr)
Inventor
Fatih M. Uckun
Osmond D'cruz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parker Hughes Institute
Original Assignee
Parker Hughes Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parker Hughes Institute filed Critical Parker Hughes Institute
Publication of EP1557197A1 publication Critical patent/EP1557197A1/de
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms

Definitions

  • the present invention is directed to novel PBT and DABO derivatives.
  • the invention is directed to novel PBT and DABO derivatives that exhibit spermicidal activity.
  • HIV Human immunodeficiency virus
  • AIDS acquired immunodeficiency syndrome
  • N-9 vaginal contraceptives containing N-9 had no effect on the transmission of HIV/AIDS and other STDs when provided as part of an overall prevention program to prevent heterosexual transmission of HIV/AIDS. See, for Example, Roddy et. al., 1998, N. Eng.J. Med . 339:504-510; Hira et.al., 1997, Int . J. STD AIDS 8:243-250)
  • New, effective, safe, and female-controlled topical microbicides lacking detergent-type membrane toxicity should have clinical advantage over the currently available vaginal microbicides.
  • Physiological fertilization depends on the ability of the ejaculated sperm to swim, bind the zona pellucida, and penetrate the egg. Each of these activities is primarily dependent on sperm motility. Therefore, adding spermicidal function to antiretroviral drugs of choice, such as non-nucleoside inhibitors (NNIs), could be an effective way to curb heterosexual vaginal transmission of HIV as well as prevent conception.
  • NNIs non-nucleoside inhibitors
  • the invention provides halogenated PBT derivatives having the chemical structure (I), or a pharmaceutically acceptable salt thereof: where R, R 1 , R 2 , R 3 , and R 4 are independently hydrogen, F, Cl, Br, or I, and where at least one of R, R 1 , R 2 , R 3 , and R 4 is F, Cl, Br, or I.
  • the invention also provides a novel DABO derivative compound comprising the formula (III): where R 1 and R 2 are alike or different, and are hydrogen, halo, alkyl, alkenyl, hydroxy, alkoxy, thioalkyl, thiol, phosphino, ROH, or RNH group, where R is alkyl; Y is S or O; and R 3 is alkyl, alkenyl, aryl, aralkyl, ROH, or RNH 2 group, where R is alkyl; or a pharmaceutically acceptable salt thereof.
  • the invention additionally provides a method of inhibiting conception in a mammal.
  • the method comprises contacting mammalian sperm with an effective spermicidal amount of a novel halogenated PBT derivative or a novel DABO derivative of the invention.
  • Another aspect of the invention is a method for inhibiting the motility of sperm.
  • the method comprises contacting sperm with a sperm mobility-inhibiting effective amount of a halogenated PBT derivative or a DABO derivative of the invention.
  • the invention also provides a composition comprising an effective spermicidal amount of a spermicidal agent, and a pharmaceutically acceptable carrier, diluent, or vehicle.
  • the spermicidal agent comprises a halogenated PBT derivative or a DABO derivative of the invention.
  • DABO means the compound dihydroalkoxybenzyloxopyrimidine.
  • S-DABO means the compound 5-isopropyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-ones.
  • PBT means the compound phenethyl-5-bromopyridylthiourea.
  • N-9 means the virucidal/spermicide, nonoxynol-9.
  • RT reverse transcriptase
  • a "nonnucleoside inhibitor (NNI)" of HIV reverse-transcriptase (HIV-RT) means a compound which binds to an allosteric site of HIV-RT, leading to noncompetitive inhibition of HIV-RT activity.
  • nonnucleoside inhibitors of HIV-RT include, but are not limited to, S-DABO, F-PBT, and D-PBT.
  • analog or “derivative” are used interchangeably to mean a chemical substance that is related structurally and functionally to another substance.
  • An analog or derivative contains a modified structure from the other substance, and maintains the function of the other substance, in this instance, maintaining the ability to interact with an NNI-RT binding site.
  • the analog or derivative need not be, but can be synthesized from the other substance.
  • a DABO analog or derivative means a compound structurally related to DABO, but not necessarily made from DABO.
  • pharmaceutically acceptable carrier includes any material which, when combined with a compound of the invention, allows the compound to retain biological activity, such as the ability to inhibit sperm activity, and is non-reactive with the subject's immune system.
  • examples include, but are not limited to, any of the standard pharmaceutical carriers such as a phosphate buffered saline solution, water, emulsions such as oil/water emulsion, and various types of wetting agents.
  • Preferred diluents for aerosol or parenteral administration are phosphate buffered saline or normal (0.9%) saline.
  • Compositions comprising such carriers are formulated by well known conventional methods (see, for example, Remington's Pharmaceutical Sciences, Chapter 43, 14th Ed., Mack Publishing Col, Easton PA 18042, USA).
  • NNIs possessing the spemicidal activity include novel derivatives of PBT and DABO.
  • the derivatives of PBT and DABO of the invention are particularly useful in forming contraceptive products that can reduce the spread of sexually transmitted diseases, specifically the spread of HIV. Contacting sperm with these spermicidal NNIs inhibits the motility of the sperm and has the desired spermicidal and/or conception-inhibiting functions.
  • PBT derivatives exhibiting significant spermicidal activity include halogen substituted PBT derivatives having the chemical structure (I) shown below, or a pharmaceutically acceptable salt thereof: where R, R 1 , R 2 , R 3 , and R 4 are independently hydrogen, F, Cl, Br, and I, and wherein at least one of R, R 1 , R 2 , R 3 , and R 4 is F, Cl, Br, or I.
  • One of the more preferred PBT derivatives of the invention is N-[2-(2-fluorophenethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (F-PBT) which has the chemical structure (II) shown below:
  • PBT derivatives of the invention can be synthesized as described in the Examples herein, and as described in Vig et al., BIOORG. MED. CHEM ., 6:1789-1797 (1998).
  • 2-amino-5-bromopyridine is condensed with 1,1-thiocarbonyl diimidazole to furnish the precursor thiocarbonyl derivative.
  • Further reaction with appropriately halogen-substituted phenylethylamine gives the target halogenated PBT derivatives.
  • DABO derivatives exhibiting significant spermicidal activity include DABO derivatives having the chemical structure (III) shown below, or a pharmaceutically acceptable salt thereof: where R 1 and R 2 are alike or different, and are hydrogen, halo, alkyl, alkenyl, hydroxy, alkoxy, thioalkyl, thiol, phosphino, ROH, or RNH group, where R is alkyl.
  • R 1 and R 2 is an alkyl having 1 to 3 carbonatones, (C 1 -C 3 ), such as methyl (Me), ethyl (Et), or isopropyl ( i -Pr).
  • R 1 is alkyl, alkenyl, ROH, or RNH 2 .
  • R 2 is preferably halo, alkyl, or C 1 -C 3 alkoxy;
  • Y is S or O, and is preferably S.
  • R 3 is alkyl, alkenyl, aryl, aralkyl, ROH, or RNH group, where R is alkyl , and is preferably C 1 -C 3 alkyl.
  • Preferred DABO derivatives include compounds having the chemical structure (IV) shown below, or a pharmaceutically acceptable salt thereof: where R 1 is Me, Et, or i -Pr and R 2 is H or Me.
  • DABO derivative compounds of the invention include compounds (a) through (d) listed below, or a pharmaceutically acceptable salt thereof:
  • One of the more preferred DABO derivatives of the invention is the compound 5-isopropyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-ones (S-DABO), and pharmaceutically acceptable salts thereof, which is exemplified by the chemical structure (V) shown below:
  • DABO derivatives can be prepared as described in the Examples herein, and as described in Vig et al., BIOORG MED CHEM LETTERS , 8:1461-1466 (1998).
  • Reagents and conditions a) R 2 CHBrCOOEt/Zn/THF, b) HCl(aq), c) (H 2 N) 2 CS/Na/EtOH,
  • ethyl-2-alkyl-4-(phenyl)-3-oxobutyrates 1a-d were obtained from commercially available phenyl acetonitrile.
  • the ⁇ -ketoesters were condensed with thiourea in the presence of sodium ethoxide to furnish the corresponding thiouracils 2a-d.
  • Compounds (1 a-d and 2 a-d) were produced by a methods previously described (Danel, K. et al., Acta Chemica Scandinavica, 1997, 51 , 426-430; Mai, A. et al., J. Med Chem., 1997, 40 , 1447-1454; Danel, K. et al., J. Med. Chem., 1998, 41 , 191-198).
  • compositions for spermicidal use can be formulated into compositions for spermicidal use.
  • Such compositions are intended particularly for use in mammals, i.e. any class of higher vertebrates that nourish their young with milk secreted from mammary glands, for example humans, rabbits and monkeys. It is also contemplated that the compositions may be used as sperm immobilization compositions. It is expected that the present invention will be used by humans in most practical applications.
  • compositions of the present invention contain one or more of spermicidal PBT and DABO derivatives, and pharmaceutically acceptable salts thereof, as disclosed above.
  • the amount of spermicidal PBT and DABO derivatives employed generally will be that amount necessary to achieve the desired spermicidal and anti-viral protective results. The amounts can be varied as needed for specific compositions.
  • the amount of spermicidal PBT and DABO derivatives will typically range from about 0.025 to 0.5 weight percent based on the total weight of the contraceptive composition.
  • the amount of the spermicidal PBT and DABO derivatives employed will be from about 0.05 to 0.5 weight percent, and more preferably from about 0.05 to 0.25 weight percent, based on the total weight of the composition.
  • compositions of the present invention may contain not only the spermicidal PBT and DABO derivatives, but also pharmaceutically acceptable carriers, diluents or vehicles as needed, i.e., materials for appropriately delivering and/or maintaining the spermicidal NNIs to a site for contact with sperm and so as to provide the desired spermicidal and/or anti-viral protective activity.
  • One advantageous component in the pharmaceutical composition for administration of a spermicide is a polymeric delivery component as described in U.S. Patent 5,595,980, which patent is incorporated herein by reference. It has been found that such polymeric delivery component enhances the effectiveness of a spermicide and reduces vaginal irritation on administration.
  • the balance of the contraceptive compositions may optionally comprise one or more cosmetic ingredients.
  • cosmetic ingredients are known to those skilled in the art and are often referred to in the art as diluents, solvents and adjuvants.
  • cosmetic ingredients include, for example; water, ethyl alcohol, isopropyl alcohol, glycerin, glycerol propylene glycol, sorbitol and other high molecular weight alcohols.
  • contraceptive compositions may contain minor amounts, e.g.
  • compositions from about 0.1 to 5% weight based on the weight of the contraceptive compositions, of other additives, such as, for example; stabilizers, surfactants, menthol, eucalyptus oil, other essential oils, fragrances, and the like.
  • additives such as, for example; stabilizers, surfactants, menthol, eucalyptus oil, other essential oils, fragrances, and the like.
  • Polyoxyethylene 20 sorbitan monolaurate is a preferred stabilizer for use in the compositions.
  • the selection and amounts of cosmetic ingredients, other additives, and blending procedures can be carried out in accordance with techniques well-known in the art.
  • the spermicidal active ingredients, and contraceptive compositions containing the same, of the present invention may be delivered to the vagina of a mammal by any means known to those skilled in the art.
  • Typical forms for delivery of the compositions include, for example; creams, lotions, gels, foams, intervaginal devices such as sponges, condoms, including female condoms, suppositories, and films.
  • the contraceptive compounds and compositions of the present invention may be used as personal care products, such as, for example, condom lubricants, and the like.
  • Such lubricants may comprise commonly known ingredients such as, for example: humectants; e.g., glycerin, sorbitol, mannitol, glycols and glycol ethers; buffers, e.g., glucono-d-lactone; germicides or bactericides; e.g., chlorhexidine gluconate; preservatives, e.g., methylparaben; viscosifiers; e.g., hydroxyethyl cellulose, etc.; other adjuvants; e.g., colors and fragrances; in addition to the compositions of the present invention.
  • humectants e.g., glycerin, sorbitol, mannitol, glycols and glycol ethers
  • buffers e.g., glucono-d-lactone
  • germicides or bactericides e.g., chlorhexidine gluconate
  • viscosity of such delivery forms may vary widely.
  • the viscosity of a gel form of the composition of the present invention e.g., 150,000 centipoise
  • the viscosity of lotion form of the composition of the present invention e.g., 100 centipoise.
  • Further details concerning the materials, ingredients, proportions and procedures of such delivery forms can be selected in accordance with techniques well-known in the art.
  • compositions of the present invention are preferably administered to a site for contacting sperm, such as to the vagina of a mammal, in a dosage which is effective to immobilize sperm, e.g. sperm present in the vagina, and/or to inhibit sperm penetration of cervical mucus.
  • Typical dosages range between about 0.0001 to 0.001 grams of the composition per kilogram of body weight of the mammal.
  • Intervaginal devices also may be used to aid in the administration of the spermicidal active ingredients or contraceptive compositions containing the same as described in U.S. Patent 5,069,906, the disclosure of which is incorporated herein by reference.
  • compositions also may be formulated to release the spermicide both rapidly and/or with a prolonged release of the drug.
  • a formulation providing both rapid and prolonged release has been described in U.S. Patent 4,707,362, which also is incorporated herein by reference.
  • the spermicidal NNIs of the invention may be incorporated into a spermicidal article such as a vaginal insert, a condom, or other such device, such that when the article is used, the spermicidal NNI may be delivered to contact sperm.
  • a spermicidal article such as a vaginal insert, a condom, or other such device, such that when the article is used, the spermicidal NNI may be delivered to contact sperm.
  • NNIs non-nucleoside inhibitors of HIV-1 reverse transcriptase
  • novel NNIs as inhibitors of HIV RT was based on a computer model in which a composite binding pocket was constructed from 9 individual crystal structures of RT-NNI complexes.
  • the novel NNIs include: N-[2-(2,5-dimethoxyphenethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (D-PBT), N-[2-(2-fluorophenethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (F-PBT), and 5-isopropyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-( 1H)-one (S-DABO).
  • the NNI trovirdine could be viewed as two chemical groups linked together by a thiourea group.
  • One half of the molecule is composed of a pyridylthiourea moiety which forms an intramolecular hydrogen-bonded heterocyclic ring.
  • the other half of the molecule is a pyridyl ring separated from the thiocarbonyl group by an ethyl linker.
  • Computer docking procedures using trovirdine revealed multiple sites which could be used for the incorporation of larger functional groups surrounding the pyridyl ring, the ethyl linker, and near the 5-bromo position of trovirdine.
  • D-PBT and F-PBT Two new PBT derivatives (D-PBT and F-PBT) were synthesized by replacing the 2-pyridyl ring of trovirdine with 2,5 dimethoxyphenyl moiety (D-PBT) or a fluorine atom at the ortho position (F-DBT).
  • D-PBT 2,5 dimethoxyphenyl moiety
  • F-DBT fluorine atom at the ortho position
  • Derivatization of DABO was achieved by modeling studies of potent HEPT derivatives and by the addition of a isopropyl group at the C-5 position of the thymine ring (S-DABO).
  • the anti-HIV activity of these three novel NNIs was compared with that of trovirdine and of the virucidal/spermicide, nonoxynol-9 (N-9), by measuring viral RT activity and p24 antigen production as markers of viral replication using HIV-infected human peripheral blood mononuclear cells (PBMCs).
  • PBMCs peripheral blood mononuclear cells
  • the effects on sperm motion kinematics and sperm membrane integrity were analyzed by computer-assisted sperm analysis (CASA) and by confocal laser scanning microscopy (CLSM), respectively.
  • NNI concentration-inhibitory effects of NNI versus N-9 against normal human ectocervical and endocervical epithelial cells were tested using the MTT assay. All three NNIs were potent inhibitors of purified recombinant HIV RT and abrogated HIV replication in PBMCs at nanomolar concentrations (IC 50 ⁇ 1 nM) when compared with N-9 or trovirdine [IC 50 values of 2.2 ⁇ M and 0.007 ⁇ M respectively].
  • Two NNIs, F-PBT and S-DABO, also exhibited concentration- and time-dependent spermicidal activity.
  • Mass spectrum analysis was performed using a Hewlett-Packard (Palo Alto, CA) Matrix Assisted Laser Description time-of-flight (MALDI-TOF) spectrometer (model G2025A) in the molecular ion detection mode (matrix used was cyanohydroxycinnamic acid). Some samples were analyzed using a Finnigan (Madison, WI) MAT 95 instrument. Elemental analysis was performed by Atlantic Microlabs (Norcross, GA).
  • Trovirdine (N-[2-(2-pyridyl)ethyl]-N'-[2-bromopyridyl)]-thiourea), was synthesized according to literature procedure. See, Cantrell et al., J MED CHEM 39:4261-4274 (1996).
  • F-PBT was synthesized according to Scheme 2.
  • 2-amino-5-bromopyridine was condensed with 1,1-thiocarbonyl diimidazole to furnish the precursor thiocarbonyl derivative.
  • the reaction mixture was heated to 100°C and stirred for 15 hours.
  • the reaction mixture was poured into ice-cold water and the suspension was stirred for 30 minutes.
  • the product was filtered, washed with water, dried, and further purified by column chromatography to furnish the target compounds in good yields.
  • ethyl-2-isopropyl-4-(phenyl)-3-oxobutyrate was obtained from commercially available phenylacetonitrile.
  • the ⁇ -ketoester was condensed with thiourea in the presence of sodium ethoxide to furnish the thiouracil.
  • the ethyl-2-isopropyl-4-(phenyl)-3-oxobutyrate and the thiouracil compounds were produced by methods previously described (Danel, K. et al., Acta Chemica Scandinavica, 1997, 51 , 426-430; Mai, A. et al., J. Med.
  • the HTLV IIIB strain of HIV-1 was propagated in CCRF-CEM cells and the virus stocks obtained from cell-free supernatants of infected cells were titered using MT-2 cells. Cell-free supernatants were harvested and frozen in 1 ml aliquots at -70°C. Titration of the stock virus was performed using MT-2 cells and the cytopathic effect of the virus used in this study was typical of HIV-1 on MT-2 cells.
  • PBMCs peripheral blood mononuclear cells
  • RPMI 1640 medium Gibco-BRL, Grand Island, NY
  • heat-inactivated fetal calf serum 3% interleukin-2, 2 mM L-glutamine, 25 mM HEPES, 2g/L NaHCO 3 , 50 ⁇ g/ml gentamicin, and 4 ⁇ g/ml phytohemagglutinin prior to exposure to HIV-1 at a multiplicity of infection of 0.1 during a 1-hour adsorption period at 37°C in a humidified 5% CO 2 atmosphere.
  • the p24 enzyme immunoassay was the unmodified kinetic assay available commercially (Coulter Corporation/Immunotech, Inc., Westbrook, ME).
  • the assay uses a murine monoclonal antibody to the HIV core protein coated onto microwell strips to which the antigen present in the test culture supernatant sample binds. Id .
  • the plates were read on a ELISA reader (Molecular Devices, Sunnyvale, CA) at 650 nm and p24 levels, expressed as ng/ml, were calculated against known standards supplied by Coulter/Immunotech, Inc. Percent viral inhibition was calculated by comparing the p24 values for the test substance-treated infected cells with the p24 values for untreated infected cells (i.e., virus controls).
  • 3 H-TTP is incorporated into the primer by reverse transcription.
  • 3 H-TTP at a final concentration of 0.5 Ci/sample was diluted in RT assay buffer (49.5 mM Tris-HCl, pH 8.0, 80 mM KCl, 10 mM MgCl 2 , 10 mM DTT, 2.5 mM EGTA, 0.05% Nonidet- P-40), and added to annealed DNA/RNA bound to SPA beads.
  • RT assay buffer 49.5 mM Tris-HCl, pH 8.0, 80 mM KCl, 10 mM MgCl 2 , 10 mM DTT, 2.5 mM EGTA, 0.05% Nonidet- P-40
  • Percent inhibition of virus replication was calculated by comparing the p24 antigen values or RT activity from the test drug-treated infected cells with p24 antigen values or RT activity from untreated infected cells.
  • the anti-HIV activity of compounds was expressed as the IC 50 values, calculated from the dose-response curves, and defined as the drug concentration that decreases the HIV-1 RT activity or p24 antigen production in HIV-1 infected PBMCs, by 50%.
  • MTA microculture tetrazolium assay
  • XTT 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)-carbonyl]-2H-tetrazolium hydroxide
  • Motile sperm ( ⁇ 10 x 10 6 /ml), were suspended in 1 ml of Biggers, Whitten, and Whittingam's medium (BWW) containing 25 mM HEPES (Irvine Scientific, Santa Ana, CA), and 0.3% BSA in the presence and absence of serial two-fold dilutions of test substance (500 ⁇ M to 31.2 ⁇ M) in 1% DMSO.
  • BWW Biggers, Whitten, and Whittingam's medium
  • the stock solutions of NNIs were prepared in DMSO (100 mM) and diluted in assay medium to yield the desired concentrations. Corresponding volume of DMSO (1%) was added to control tubes.
  • N-9 was diluted in BWW-0.3% BSA (pH 7.4) to yield the desired concentrations (31.2 ⁇ M to 500 ⁇ M).
  • the percentage of motile sperm was evaluated by CASA by procedures as described in D'Cruz et al., BIOL REPROD , 58:1515-1526, (1998); and D'Cruz et al., MOL HUM REPROD , 4:683-693 (1998).
  • the percent motilities were compared with sham-treated control suspensions of motile sperm.
  • the spermicidal activity of test compounds was expressed as the EC 50 (the final concentration of the compound in medium that decreases the proportion of motile sperm by 50%).
  • motile fractions of sperm (10 7 /ml) were incubated at 37°C in BWW-0.3% BSA in the presence of 1 mM F-PBT, S-DABO in 1% DMSO or 1% DMSO alone as vehicle control. At timed intervals of 5 or 10 minutes, duplicate aliquots (4- ⁇ l) were transferred to two 20 ⁇ m Microcell chambers (Conception Technologies) and sperm motility was assessed by CASA for a duration of 60 minutes.
  • minimum contrast 8 minimum contrast 8; minimum size 6; low-size gate, 1.0; high-size gate, 2.9; low-intensity gate, 0.6; high-intensity gate, 1.4; phase-contrast illumination; low path velocity at 10 ⁇ m/s, and threshold straightness at 80%; and magnification factor, 1.95.
  • VCL curvilinear velocity
  • VAP
  • the percentages of sperm with an intact acrosome following a 6 hour treatment with and without increasing concentrations (31.2 ⁇ M to 500 ⁇ M) of the three NNIs (S-DABO, F-PBT and D-PBT) in comparison to N-9 were evaluated by CLSM. Ethanol permeabilized and air-dried sperm smears were stained sequentially with the three fluorescent markers, FITC- Pisum sativum lectin, TOTO- 3 iodide, and Nile red (Molecular Probes, Eugene, OR) because their targets are different (acrosome, nucleus, and membrane lipid respectively).
  • Digitized images were saved on a Jaz disk (Iomega Corporation, Roy, UT) and processed using Lasersharp (Bio-Rad) with the Adobe Photoshop software (Adobe Systems, Mountain View, CA). Final images were printed on a Fuji Pictrography 3000 (Fuji Photo Film Co., Tokyo, Japan) color printer.
  • MTT 3-[4,5-dimethyl thiazol-2-yl]-2,5-diphenyltetrazolium bromide
  • cells were harvested with 0.125% (w/v) trypsin-0.02% EDTA (GIBCO) from exponential-phase maintenance cultures and centrifuged (300 g ⁇ 5 minutes). After suspension and counting, cells were dispensed within triplicate 96-well tissue culture plates in 100 ⁇ l volumes. After 3 and 24 hour incubation, the culture medium was discarded and replaced with 100 ⁇ l of fresh medium containing serial two-fold dilutions of drugs in medium to yield 3.9 ⁇ M to 250 ⁇ M for N-9 and 250 ⁇ M to 4 mM for F-PBT and S-DABO. NNIs were reconstituted in DMSO to a concentration of 100 mM. Stock solution of N-9 was made in sterile PBS.
  • Control wells with medium containing 0.25% of DMSO alone were included as controls. Culture plates were then incubated for 24 hour before adding 10 ⁇ l of MTT solution (5 mg/ml in PBS) to each well. Wells containing only medium and MTT were used as control for each plate. The tetrazolium/formazan reaction was allowed to proceed for 4 hours at 37°C, and then 100 ⁇ l of the solubilization buffer (10% sodium dodecyl sulfate in 0.1% HCl) was added to all wells and mixed thoroughly to dissolve the dark blue formazan crystals.
  • MTT solution 5 mg/ml in PBS
  • Wells containing only medium and MTT were used as control for each plate.
  • the tetrazolium/formazan reaction was allowed to proceed for 4 hours at 37°C, and then 100 ⁇ l of the solubilization buffer (10% sodium dodecyl sulfate in 0.1% HCl) was added to all wells and mixed thoroughly to dissolve the dark blue formazan crystal
  • Results are presented as the mean or mean ⁇ SD values from independent measurements. The statistical significance of difference between test groups was analyzed by one-way analysis of vairance and Dunnett's multiple comaparison test. Linear regression analysis was used to find correlated values between two measured parameters. A p value of ⁇ 0.05 was considered significant. Non-linear regression analysis were used to find IC 50 and EC 50 values from the concentration effect curves using the GraphPad PRISM version 2.0 software program (San Diego, CA).
  • D-PBT and F-PBT were 2- to 8-fold more potent than trovirdine in inhibiting recombinant HIV RT.
  • the observed reduction in RT activity and p24 production by the 3 NNIs were not due to any cytotoxic effects by these new agents since cell viability of PBMC was not affected even at the highest concentrations tested (IC 50 [MTA] >100 ⁇ M).
  • sperm motion kinematics using CASA confirmed that trovirdine or D-PBT treatment did not alter the sperm motion parameters, such as the progressive motility (PRG), track speed (VCL), path velocity (VAP), straight line velocity (VLS), straightness of the swimming pattern (STR), linearity of the sperm tracks (LIN), beat-cross frequency (BCF), and the amplitude of lateral sperm-head displacement (ALH).
  • PRG progressive motility
  • VCL track speed
  • VAP path velocity
  • VLS straight line velocity
  • STR straightness of the swimming pattern
  • LIN linearity of the sperm tracks
  • BCF beat-cross frequency
  • AH amplitude of lateral sperm-head displacement
  • the EC 50 value of 147 ⁇ M (95% CI: 94-330 ⁇ M) obtained for F-PBT was within the spermicidal range of N-9 (EC 50 value 81 ⁇ M; 95% CI: 41-410 ⁇ M) (see Figure 2 and Table 1).
  • the evaluation of the kinetics of sperm immobilization by CASA showed a linear relationship between incubation time and loss of progressive sperm motility after exposure to compound F-PBT (correlation coefficient 0.811, p ⁇ 0.005) (see Figure 3).
  • the time required for 50% motility loss of progressively motile sperm exposed to F-PBT was 10 minutes (95% CI : 8-12 minutes).
  • the sperm motility in control samples remained stable (95% ⁇ 3% compared to baseline) during the 60 minutes monitoring period.
  • the time-dependent sperm motility loss (PRG) induced by F-PBT was associated with significant changes in the movement characteristics of the surviving sperm particularly with respect to the track speed (VCL), path velocity (VAP), and straight line velocity (VSL).
  • VCL track speed
  • VAP path velocity
  • VSL straight line velocity
  • the representative sperm kinematic parameters of F-PBT-treated sperm versus time is shown in Figure 4.
  • the decreases in VSL and VCL or VSL and VAP were similar in magnitude. Therefore, values for linearity (LIN) of the sperm tracks and the straightness (STR) of the swimming pattern remained relatively constant.
  • the beat cross frequency (BCF), and the amplitude of lateral sperm-head displacement (ALH) were relatively stable as the proportion of motile sperm declined during the linear phase of motility loss.
  • the sperm motion parameters of control sperm showed no significant changes during the 60 minutes incubation period.
  • Nonoxynol-9 the most widely used vaginal spermicide, immobilizes sperm as a result of a detergent-type action on the sperm plasma membrane. Because of its membrane disruptive properties, continued use of N-9 has been shown to damage the cervicovaginal epithelium, cause an acute tissue inflammatory response, and enhance the likelihood of HIV infection by heterosexual transmission. A spermicide that does not elicit any non-specific membrane toxicity characteristic of detergent-type contraceptives would offer clinical advantages.
  • the MTT assay measuring the cell proliferation and viability was used to test the in vitro cytotoxicity of F-PBT and S-DABO in comparison to N-9 against confluent monolayers of normal human ectocervical and endocervical epithelial cells. Cells were exposed to these compounds at doses ranging from 3.9 ⁇ M to 4 mM for 3 hours or 24 hours. The concentration-response cell survival curves for F-PBT and S-DABO versus N-9 for these cells measured by the MTT assay were compared with spermicidal activity measured by CASA.
  • N-9 exhibited significant cytotoxicity to ectocervical epithelial and endocervical epithelial cells with mean IC 50 values of 15 ⁇ M and 11 ⁇ M, respectively.
  • IC 50 values for F-PBT and S-DABO dose survival curves for ectocervical and endocervical epithelial cells were >4 mM for S-DABO and >1mM for F-PBT respectively ( see Table 2).
  • N-9 was spermicidal only at cytotoxic concentrations (EC 50 value: 81 ⁇ M; selectivity indices: 0.18 and 0.13 for ectocervical and endocervical cells respectively), whereas, F-PBT and S-DABO showed high selectivity indices against these cells (SI: >6.8 and >19.8 for ectocervical cells and endocervical cells respectively). Thus, F-PBT and S-DABO were significantly less active against these reproductive tract cells.
  • NNIs have been found to bind to a specific allosteric site of HIV-1 RT near the polymerase site and interfere with reverse transcription by altering either the conformation or mobility of RT, thereby leading to noncompetitive inhibition of the enzyme.
  • a number of amino acid residues in contact with the NNIs are relatively flexible and vary from structure to structure and can be displaced by the right NNI. These residues include Tyr180, Tyr181, Tyr318, Try319, Phe227, Leu234, Trp229, Pro95, and Glu138 (from p51 subunit of RT).
  • the enhanced anti-HIV activity of the novel PBT and DABO derivatives studied here is most likely due to their larger molecular surface favoring the binding pocket of NNI, as well as to greater lipophilicity (due to substitution of a bulkier dimethoxyphenyl group in place of phenyl ring), better hydrophobic contact (due to the substitution of isopropyl at the C-5 position of the thymine ring), and closer contact (due to substitution of methoxy groups at meta / ortho positions or fluoro group at the ortho position of the unsubstituted phenyl ring) with target amino acid residues, Pro95 and Trp229 of RT (44,45).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Saccharide Compounds (AREA)
EP04030236A 1998-12-31 1999-12-29 Dihydroalkoxybenzyloxopyrimidin (dabo) Derivative mit spermizider Wirkung Withdrawn EP1557197A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/224,677 US6136335A (en) 1998-12-31 1998-12-31 Phenethyl-5-bromopyridylthiourea (PBT) and dihydroalkoxybenzyloxopyrimidine (DABO) derivatives exhibiting spermicidal activity
US224677 1998-12-31
EP99967737A EP1140848B1 (de) 1998-12-31 1999-12-29 Phenethyl-5-bromopyridylthioharnstoff (pbt) derivative mit spermizider wirkung

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP99967737A Division EP1140848B1 (de) 1998-12-31 1999-12-29 Phenethyl-5-bromopyridylthioharnstoff (pbt) derivative mit spermizider wirkung

Publications (1)

Publication Number Publication Date
EP1557197A1 true EP1557197A1 (de) 2005-07-27

Family

ID=22841684

Family Applications (2)

Application Number Title Priority Date Filing Date
EP99967737A Expired - Lifetime EP1140848B1 (de) 1998-12-31 1999-12-29 Phenethyl-5-bromopyridylthioharnstoff (pbt) derivative mit spermizider wirkung
EP04030236A Withdrawn EP1557197A1 (de) 1998-12-31 1999-12-29 Dihydroalkoxybenzyloxopyrimidin (dabo) Derivative mit spermizider Wirkung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP99967737A Expired - Lifetime EP1140848B1 (de) 1998-12-31 1999-12-29 Phenethyl-5-bromopyridylthioharnstoff (pbt) derivative mit spermizider wirkung

Country Status (15)

Country Link
US (2) US6136335A (de)
EP (2) EP1140848B1 (de)
JP (1) JP2002533444A (de)
KR (1) KR20010082772A (de)
CN (1) CN1371367A (de)
AT (1) ATE306475T1 (de)
AU (1) AU2396800A (de)
BR (1) BR9916620A (de)
CA (1) CA2362492A1 (de)
DE (1) DE69927710T2 (de)
HU (1) HUP0104904A2 (de)
IL (1) IL143508A0 (de)
MX (1) MXPA01006746A (de)
NO (1) NO20012817L (de)
WO (1) WO2000039095A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101628996B (zh) * 2008-07-18 2012-05-30 绿神（北京）乳胶业有限公司 一种乳胶避孕套的制备方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1305313B1 (it) * 1998-07-17 2001-05-04 Colla Paolo 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
US6136335A (en) * 1998-12-31 2000-10-24 Hughes Institute Phenethyl-5-bromopyridylthiourea (PBT) and dihydroalkoxybenzyloxopyrimidine (DABO) derivatives exhibiting spermicidal activity
US7064114B2 (en) * 1999-03-19 2006-06-20 Parker Hughes Institute Gel-microemulsion formulations
BR0115474A (pt) * 2000-11-17 2006-01-31 Idenix Cayman Ltd Composição e método para inibição da transmissão de hiv que usam 6-benzil-4-oxopirimidinas substituìdas aplicada por via tópica
SE0100733D0 (sv) 2001-03-05 2001-03-05 Medivir Ab Non-nucleoside reverse transcriptase inhibitors
SE0102867D0 (sv) 2001-08-28 2001-08-28 Medivir Ab Non-nucleoside reverse transcriptase inhibitors
US6929945B2 (en) * 2002-12-09 2005-08-16 Advanced Fluidix Laboratories Llc Male fertility assay method and device
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
PL2247603T3 (pl) 2008-02-12 2017-04-28 Dow Agrosciences Llc Kompozycje szkodnikobójcze
US8748340B2 (en) * 2011-02-09 2014-06-10 Dow AgroSciecnes LLC. Pesticidal compositions and processes related thereto
WO2013009791A1 (en) 2011-07-12 2013-01-17 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
CN103193771B (zh) * 2013-03-29 2015-08-05 中国人民解放军军事医学科学院生物工程研究所 链状酰胺类ccr5受体抑制剂的药物新用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047501A2 (en) * 1998-03-17 1999-09-23 Parker Hughes Institute Nonnucleoside inhibitors of reverse transcriptase for the treatment of hiv-infection
WO2000003998A1 (en) * 1998-07-17 2000-01-27 Novirio Pharmaceuticals Limited Substituted 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions containing them

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009213A1 (en) 1988-03-31 1989-10-05 Mitsubishi Kasei Corporation 6-substituted acyclicpyrimidine nucleoside derivatives and antiviral agents containing same as active ingredients
US5686428A (en) * 1989-04-07 1997-11-11 Aktiebolaget Astra Pharmaceutical composition
HU205917B (en) * 1989-09-29 1992-07-28 Mitsubishi Chem Ind Process for producing 6-substituted pyrimidine derivatives and antiviral pharmaceutical compositions containing them as active components
US5503978A (en) * 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5593993A (en) * 1991-08-02 1997-01-14 Medivir Ab Method for inhibition of HIV related viruses
IL102548A (en) * 1991-08-02 1998-08-16 Medivir Ab Use of painting derivatives in the preparation of drugs for VIH inhibition and treatment of SDIA and new compounds
JPH0725770A (ja) * 1993-07-09 1995-01-27 Mitsubishi Chem Corp 経皮吸収性抗ウイルス剤
NZ273741A (en) * 1993-08-24 2000-06-23 Medivir Ab Heterocyclically-substituted guanidine, urea and thiourea derivatives
US6136335A (en) * 1998-12-31 2000-10-24 Hughes Institute Phenethyl-5-bromopyridylthiourea (PBT) and dihydroalkoxybenzyloxopyrimidine (DABO) derivatives exhibiting spermicidal activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047501A2 (en) * 1998-03-17 1999-09-23 Parker Hughes Institute Nonnucleoside inhibitors of reverse transcriptase for the treatment of hiv-infection
WO2000003998A1 (en) * 1998-07-17 2000-01-27 Novirio Pharmaceuticals Limited Substituted 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions containing them

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D'CRUZ ET AL: "Aryl phosphate derivatives of bromo-methoxy-azidothymidine are dual-function spermicides with potent anti-human immunodeficiency virus", BIOLOGY OF REPRODUCTION,US,ORLANDO, FL, vol. 59, September 1998 (1998-09-01), pages 503 - 515, XP002109805, ISSN: 0006-3363 *
D'CRUZ O J ET AL: "Novel derivatives of phenethyl-5-bromopyridylthiourea and dihydroalkoxybenzyl-oxopyrimidine are dual-function spermicides with potent anti-human immunodeficiency virus activity", BIOLOGY OF REPRODUCTION, SOCIETY FOR THE STUDY OF REPRODUCTION, CHAMPAIGN, IL, US, vol. 1, no. 1, 1999, pages 1419 - 1428, XP000886836, ISSN: 0006-3363 *
VIG R ET AL: "5-alkyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-ones as potent non-nucleoside reverse transcriptase inhibitors of S-DABO series", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 8, no. 12, 16 June 1998 (1998-06-16), pages 1461 - 1466, XP004137064, ISSN: 0960-894X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101628996B (zh) * 2008-07-18 2012-05-30 绿神（北京）乳胶业有限公司 一种乳胶避孕套的制备方法

Also Published As

Publication number Publication date
BR9916620A (pt) 2001-09-25
HUP0104904A2 (hu) 2002-04-29
EP1140848A2 (de) 2001-10-10
AU2396800A (en) 2000-07-31
EP1140848B1 (de) 2005-10-12
NO20012817L (no) 2001-08-29
MXPA01006746A (es) 2002-04-24
WO2000039095A2 (en) 2000-07-06
IL143508A0 (en) 2002-04-21
CA2362492A1 (en) 2000-07-06
DE69927710T2 (de) 2006-07-20
NO20012817D0 (no) 2001-06-07
WO2000039095A3 (en) 2000-11-09
CN1371367A (zh) 2002-09-25
JP2002533444A (ja) 2002-10-08
ATE306475T1 (de) 2005-10-15
DE69927710D1 (de) 2006-02-23
US6136335A (en) 2000-10-24
US6376504B1 (en) 2002-04-23
KR20010082772A (ko) 2001-08-30
WO2000039095B1 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
US6136335A (en) Phenethyl-5-bromopyridylthiourea (PBT) and dihydroalkoxybenzyloxopyrimidine (DABO) derivatives exhibiting spermicidal activity
JP2559699B2 (ja) 新規なアリ−ル誘導体
EP0051879B1 (de) Substituierte Pyrimidine, ihre Synthese und diese enthaltende Zusammensetzungen, ihre Verwendung in der Arzneikunde und Zwischenprodukte für deren Synthese
TWI221471B (en) Dimethanesulfonyl anilide derivatives, process for the preparation of them and herbicides containing them as the active ingredient
DE60025848T2 (de) Pyrimidin-derivate als selective inhibitoren von cox-2
KR20050102094A (ko) Ｈｉｖ 감염 예방용 피리미딘 유도체
US6911450B1 (en) Pyrimidine acyclonucleoside derivatives, preparation method and use thereof
D'Cruz et al. Novel derivatives of phenethyl-5-bromopyridylthiourea and dihydroalkoxybenzyloxopyrimidine are dual-function spermicides with potent anti-human immunodeficiency virus activity
US6911460B2 (en) Antiviral agents and methods of treating viral infections
US5026726A (en) Gossylic iminolactones and gossylic lactones and their anti-viral activities
WO1999048902A1 (en) Azt derivatives exhibiting spermicidal and anti-viral activity
EP0115657B1 (de) Aminoalkylsulfonsäure-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
US6482805B2 (en) AZT derivatives exhibiting spermicidal and anti-viral activity
US6774139B1 (en) Dual function microbicides
CA1307222C (en) Thiadiazole antiviral agents
DE60001581T2 (de) Ethylthiophen-thioharnstoff-derivate und ihre verwendung
EP1259229A2 (de) Verwendung von benzo-thieno[2,3-d]pyrimidinen mit pde v-inhibitorischer wirkung zur behandlung von erektiler dysfunktion
JP2004519477A (ja) Ｈｉｖ抑制ｎ−アミノイミダゾール誘導体
US20140323420A1 (en) Reducing transmission of sexually transmitted infections
US6727265B2 (en) Phenoxyethyl-thiourea-pyridine compounds and their use for treatment of HIV-infections
US20020151568A1 (en) Piperidinylethyl-, phenoxyethyl-, and beta-fluorophenethyl-substituted thiourea compounds with potent anti-HIV activity
JPS6139947B2 (de)
AU2007214351A1 (en) Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines
JPH07504176A (ja) 新規及び公知のジスルフィド及びその使用
WO2002032873A1 (en) Phenoxyethyl-thiourea-pyridine compounds and their use for the treatment of hiv-infections

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050107

AC Divisional application: reference to earlier application

Ref document number: 1140848

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: D'CRUZ, OSMOND

Inventor name: UCKUN, FATIH, M.

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20060822

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070302